<SEC-DOCUMENT>0001628280-23-006049.txt : 20230302
<SEC-HEADER>0001628280-23-006049.hdr.sgml : 20230302
<ACCEPTANCE-DATETIME>20230302161401
ACCESSION NUMBER:		0001628280-23-006049
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230302
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230302
DATE AS OF CHANGE:		20230302

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cardiff Oncology, Inc.
		CENTRAL INDEX KEY:			0001213037
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				272004382
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35558
		FILM NUMBER:		23699083

	BUSINESS ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-952-7570

	MAIL ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trovagene, Inc.
		DATE OF NAME CHANGE:	20130304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrovaGene Inc.
		DATE OF NAME CHANGE:	20110830

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XENOMICS INC
		DATE OF NAME CHANGE:	20040719
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>crdf-20230302.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:538b48b5-ef5a-4299-8be5-13fa1ff9c664,g:b76e2ec4-f994-43cd-8855-d451b90cc959,d:567efde225c64486852400e5e6ad04c3--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>crdf-20230302</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM180L2ZyYWc6ZWU2MDNkMGZjZGI5NDBhMmJkMjEyOTM4YWI1MGVhYTUvdGFibGU6YzViZTc3ZjA5MmVlNDBiNmE3MTc2OTk0YTk5NmJhN2EvdGFibGVyYW5nZTpjNWJlNzdmMDkyZWU0MGI2YTcxNzY5OTRhOTk2YmE3YV8yLTEtMS0xLTQ2NjI2_2aa4ce15-8763-4ab7-8d4a-d4ad9336be6a">0001213037</ix:nonNumeric><ix:nonNumeric contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM180L2ZyYWc6ZWU2MDNkMGZjZGI5NDBhMmJkMjEyOTM4YWI1MGVhYTUvdGFibGU6YzViZTc3ZjA5MmVlNDBiNmE3MTc2OTk0YTk5NmJhN2EvdGFibGVyYW5nZTpjNWJlNzdmMDkyZWU0MGI2YTcxNzY5OTRhOTk2YmE3YV8zLTEtMS0xLTQ2NjI2_83ee30b4-39b7-4cf4-beb4-45d451ac7699">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="crdf-20230302.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-02</xbrli:startDate><xbrli:endDate>2023-03-02</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i567efde225c64486852400e5e6ad04c3_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGV4dHJlZ2lvbjo1MDc3MDc1ZjA0OTU0MjY3ODQ2OGJjYjRmNmYwOWQwMl8yNzcz_a3d28a2f-caa6-4e21-89e9-bb0411753406">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGV4dHJlZ2lvbjo1MDc3MDc1ZjA0OTU0MjY3ODQ2OGJjYjRmNmYwOWQwMl8yMjg_d9f6e7b9-b875-4e97-902b-edeadeda61cf">March 2, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><img src="crdf-20230302_g1.jpg" alt="crdf-20230302_g1.jpg" style="height:44px;margin-bottom:5pt;vertical-align:text-bottom;width:157px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGV4dHJlZ2lvbjo1MDc3MDc1ZjA0OTU0MjY3ODQ2OGJjYjRmNmYwOWQwMl8yNzY5_7e53eb6e-79b6-4444-b469-cd8e22d38e61">Cardiff Oncology,&#160;Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGFibGU6ZTQxYTdlNjQ2N2JkNDdkZDkwZGRhMGVkMmI3ZThjNmQvdGFibGVyYW5nZTplNDFhN2U2NDY3YmQ0N2RkOTBkZGEwZWQyYjdlOGM2ZF8wLTAtMS0xLTQ2NjI2_45842e66-2f80-4052-a4b4-fababe514695">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGFibGU6ZTQxYTdlNjQ2N2JkNDdkZDkwZGRhMGVkMmI3ZThjNmQvdGFibGVyYW5nZTplNDFhN2U2NDY3YmQ0N2RkOTBkZGEwZWQyYjdlOGM2ZF8wLTEtMS0xLTQ2NjI2_44114d42-d9e0-4d4e-a67e-520e94c4e67f">001-35558</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGFibGU6ZTQxYTdlNjQ2N2JkNDdkZDkwZGRhMGVkMmI3ZThjNmQvdGFibGVyYW5nZTplNDFhN2U2NDY3YmQ0N2RkOTBkZGEwZWQyYjdlOGM2ZF8wLTItMS0xLTQ2NjI2_614711e3-d0c3-4d43-afd9-9b31d1c4497b">27-2004382</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRS Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification No.)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGV4dHJlZ2lvbjo1MDc3MDc1ZjA0OTU0MjY3ODQ2OGJjYjRmNmYwOWQwMl8yNzgx_dfd9a8f7-8cbb-4e36-94d1-04c9c472cb22">11055 Flintkote Avenue</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGV4dHJlZ2lvbjo1MDc3MDc1ZjA0OTU0MjY3ODQ2OGJjYjRmNmYwOWQwMl8yNzgy_3f8117ae-2c3c-47ba-b51b-3b0d378f1722">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGV4dHJlZ2lvbjo1MDc3MDc1ZjA0OTU0MjY3ODQ2OGJjYjRmNmYwOWQwMl8yNzc2_9f7ac7c1-8acd-4bed-97c0-fc1ca095f134">CA</ix:nonNumeric> <ix:nonNumeric contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGV4dHJlZ2lvbjo1MDc3MDc1ZjA0OTU0MjY3ODQ2OGJjYjRmNmYwOWQwMl8yNzc3_152a0c53-1c49-4aef-9a36-e345d240c664">92121</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGV4dHJlZ2lvbjo1MDc3MDc1ZjA0OTU0MjY3ODQ2OGJjYjRmNmYwOWQwMl8yNzgz_d6ba076c-163c-416c-b852-39a1cd7d107c">(858)</ix:nonNumeric> <ix:nonNumeric contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGV4dHJlZ2lvbjo1MDc3MDc1ZjA0OTU0MjY3ODQ2OGJjYjRmNmYwOWQwMl8yNzc5_e1409b7e-1097-4a03-92e5-b30074e684e3">952-7570</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160; </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:3pt solid #ffffff;border-top:3pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title&#160;of&#160;each&#160;class:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="border-top:3pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading&#160;Symbol(s)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="border-right:3pt solid #ffffff;border-top:3pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGFibGU6NzJmNWNhYWFjMTJmNDMwZDgyNzdmMDdiODJhMDdhYzAvdGFibGVyYW5nZTo3MmY1Y2FhYWMxMmY0MzBkODI3N2YwN2I4MmEwN2FjMF8xLTAtMS0xLTQ2NjI2_865f921f-15bf-4164-90ef-1fc83916dc9c">Common Stock</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGFibGU6NzJmNWNhYWFjMTJmNDMwZDgyNzdmMDdiODJhMDdhYzAvdGFibGVyYW5nZTo3MmY1Y2FhYWMxMmY0MzBkODI3N2YwN2I4MmEwN2FjMF8xLTItMS0xLTQ2NjI2_03b629bc-e456-425e-a2a8-3b911a70b7e9">CRDF</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Capital Market</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302" name="dei:WrittenCommunications" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGV4dHJlZ2lvbjo1MDc3MDc1ZjA0OTU0MjY3ODQ2OGJjYjRmNmYwOWQwMl8yNzcw_8ac3a7e8-b7cf-470c-b2c1-230ad3c1bd39">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Written communication pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGV4dHJlZ2lvbjo1MDc3MDc1ZjA0OTU0MjY3ODQ2OGJjYjRmNmYwOWQwMl8yNzcx_e48b704f-cb96-4fb9-bca9-71f609438329">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGV4dHJlZ2lvbjo1MDc3MDc1ZjA0OTU0MjY3ODQ2OGJjYjRmNmYwOWQwMl8yNzcy_bbe295b6-7acd-47de-9fe0-f2ffa85b47b8">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGV4dHJlZ2lvbjo1MDc3MDc1ZjA0OTU0MjY3ODQ2OGJjYjRmNmYwOWQwMl8yNzgw_5a6a22e0-7475-48e4-bb61-03c22f548180">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">&#160;Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).&#160; Emerging growth company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:138%"><ix:nonNumeric contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGV4dHJlZ2lvbjo1MDc3MDc1ZjA0OTU0MjY3ODQ2OGJjYjRmNmYwOWQwMl8yNzc0_e03f7c07-6b6a-4ffe-bd1a-f4ec7bf3e576">o</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Item 2.02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:103%">              </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Results of Operations and Financial Conditions.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 2, 2023, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the fourth quarter and fiscal year ended December 31, 2022.  A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.</span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01. Financial Statements and Exhibits</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.363%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.437%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="crdf3222-q42022pr.htm">Press Release of Cardiff Oncology, Inc. dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="crdf3222-q42022pr.htm">March 2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="crdf3222-q42022pr.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="crdf3222-q42022pr.htm">3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURE</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> March 2, 2023</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CARDIFF ONCOLOGY,&#160;INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark Erlander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>crdf3222-q42022pr.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie0c292163e3b43e1959d3660aebead12_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><img alt="image_0.jpg" src="image_0.jpg" style="height:43px;margin-bottom:5pt;vertical-align:text-bottom;width:159px"></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:18pt;font-weight:700;line-height:112%">Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Phase 1b&#47;2 trial in lead KRAS-mutated metastatic colorectal cancer (mCRC) program continues to show our lead candidate onvansertib demonstrates an objective response rate, durability and progression-free survival that substantially exceed those seen in historical control trials</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Strengthened leadership team with appointments of Fairooz Kabbinavar, MD, FACP, as CMO, Tod Smeal, Ph.D., as CSO and Charles Monahan, R.Ph., as SVP, regulatory affairs</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Multiple data readouts expected from clinical programs and IITs in 2023</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Strong cash financial position of approximately $105.3 million at December 31, 2022&#59; projected runway into 2025</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">SAN DIEGO, March 2, 2023 </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8211; Cardiff Oncology, Inc. (Nasdaq&#58; CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;2022 was an important year for demonstrating the benefits onvansertib could bring to patients with KRAS-mutated mCRC, an area where no targeted therapies are currently approved. The results of our Phase 1b&#47;2 trial in KRAS-mutated mCRC continue to show onvansertib plus standard-of-care was well-tolerated and outperformed historical control trials on key endpoints including the durability of response. Furthermore, we observed an unexpectedly high objective response rate and progression-free survival in the bevacizumab-na&#239;ve subgroup of patients which will be evaluated in the ongoing ONSEMBLE trial,&#8221; said Mark Erlander, PhD, chief executive officer of Cardiff Oncology. &#8220;Looking forward, this will be an important year for advancing our ONSEMBLE randomized Phase 2 trial and generating additional safety and efficacy signals from our other company-sponsored and investigator-initiated clinical programs.&#8221; </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;As we build on these findings and accelerate onvansertib&#8217;s clinical development, we will benefit greatly from the deep clinical expertise of our new CMO, Dr. Fairooz Kabbinavar, who served as the lead investigator for two practice-changing trials of bevacizumab combinations leading to the approval of bevacizumab in mCRC,&#8221; continued Dr. Erlander. &#8220;We are confident we can fund our onvansertib clinical programs into 2025, and we believe our clinical data supports our approach to leveraging PLK1 inhibition to address current gaps in cancer therapies and make an important contribution to oncology patient care.&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Upcoming potential milestones</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.8pt">mPDAC data readout from Phase 2 trial expected Q2&#47;Q3 &#8217;23</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.8pt">SCLC data readout from investigator-initiated (with UPMC) Phase 2 trial expected Q2&#47;Q3 &#8217;23</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.8pt">TNBC data readout from investigator-initiated (with Dana-Farber Cancer Institute) Phase 1b&#47;2 trial expected Q4 &#8216;23&#47;Q1 &#8216;24</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.8pt">mCRC randomized data readout from Phase 2 ONSEMBLE trial expected Q3&#47;Q4 &#8216;24</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Company highlights for the year ended December 31, 2022, and subsequent weeks include&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:13.8pt">Strengthened management team with appointments of Fairooz Kabbinavar, MD, FACP, as CMO, Tod Smeal, Ph.D., as CSO and Charles Monahan, R.Ph., SVP, regulatory affairs. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Overseeing the clinical development program for onvansertib, Dr. Kabbinavar brings world class capabilities and deep expertise in colorectal cancer and other solid tumor indications to Cardiff Oncology from his 30-plus years of experience across the academic and biotech&#47;pharmaceutical sectors. During his time as an academic oncologist, he was the lead investigator on two practice-changing clinical trials of bevacizumab (Avastin&#174;) combinations leading to approval of bevacizumab in mCRC</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">1,2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. As principal medical director of Genentech&#8217;s immuno-oncology program, he led the clinical development of atezolizumab (TECENTRIQ&#174;) in extensive stage small cell lung cancer and oversaw the filing of the supplemental biologics license application that led to the drug&#8217;s FDA approval. Dr. Smeal has over 20 years of industry experience developing targeted therapies and previously served as CSO of Cancer Biology at Eli Lilly and Company, and director of the Oncology Research Unit of Pfizer. Mr. Monahan is a registered pharmacist with over 20 years of regulatory experience developing drugs and biologics for oncology, infectious diseases, and ocular indications. Prior to joining Cardiff Oncology, he most recently served as the global head of regulatory affairs for Erytech PharmaSA.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:13.8pt">Announced ONSEMBLE, a Phase 2, open-label, randomized trial for second line treatment of KRAS&#47;NRAS-mutated mCRC, as the next step in our mCRC clinical development program</font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> We designed the ONSEMBLE trial to corroborate the robust efficacy signal observed in the Phase 1b&#47;2 trial of onvansertib plus standard-of-care (SoC) FOLFIRI&#47;bevacizumab in second-line KRAS-mutated mCRC, demonstrate onvansertib's contribution above SoC alone and confirm the optimal dose. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:13.8pt">Presented robust data from the Phase 1b&#47;2 trial of onvansertib plus FOLFIRI&#47;bevacizumab in second line KRAS-mutated mCRC on a company webcast in September 2022. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Objective response rate (ORR) across all evaluable patients was 35% (n&#61;48) as compared to an ORR of 5-13% observed historically, and the median duration of response (mDoR) across all evaluable patients was 11.7 months. Median progression-free survival (mPFS) was 9.3 months across all evaluable patients, as compared to mPFS of &#126;4.5 &#8211; 5.7 months observed historically in combination trials that included the standard-of-care FOLFIRI with bevacizumab.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">3-6</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:13.8pt">Completed subgroup analysis from Phase 1b&#47;2 mCRC trial shows improved ORR and mPFS in bevacizumab-na&#239;ve patients.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> A subgroup analysis from the ongoing Phase 1b&#47;2 clinical trial of onvansertib plus FOLFIRI&#47;bevacizumab in second line KRAS-mutated mCRC showed an ORR of 69% and mPFS of 13.5 months in bevacizumab na&#239;ve patients (n&#61;13). These data compare favorably to historical control trials in mCRC, which show an ORR of approximately 25% and a mPFS of approximately 6.9 months in bevacizumab na&#239;ve patients</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">6-11</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:13.8pt">Data presented at the ESMO Congress 2022 suggest combining onvansertib with irinotecan (a component of FOLFIRI) overcomes irinotecan-resistance in RAS-mutated mCRC.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> Findings from our Expanded Access Program (EAP) of onvansertib in KRAS-mutated mCRC as well as preclinical data from patient-derived xenograft (PDX) models of irinotecan-resistant, RAS-mutated mCRC were featured in a poster at the ESMO Congress 2022 showing EAP patients with prior irinotecan treatment (43 of 51) showed clinical benefit following treatment and the combination of onvansertib and irinotecan showed significantly greater anti-tumor activity compared to onvansertib monotherapy in 5 of 6 tested PDX models of irinotecan-resistant, RAS-mutated mCRC.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:13.8pt">Presented preliminary data from our clinical trial in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC).</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> Preliminary data from five evaluable patients in an ongoing open-label Phase 2 trial of onvansertib in combination with nanoliposomal irinotecan and 5-FU in second-line metastatic PDAC provide early signal of efficacy and compare favorably to historical control trials.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">Enrolled first patients in two investigator-initiated trials in triple negative breast cancer (TNBC) and small cell lung cancer (SCLC).</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;text-decoration:underline">Full Year 2022 Financial Results&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Liquidity, cash burn, and cash runway</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As of December 31, 2022, Cardiff Oncology had approximately $105.3 million in cash, cash equivalents, and short-term investments. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Net cash used in operating activities for the full year 2022 was approximately $33.8 million, an increase of approximately $10.8 million from $23.0 million for the same period in 2021. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Based on its current expectations and projections, the Company believes its current cash resources are sufficient to fund its operations into 2025.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Operating results</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Total operating expenses were approximately $40.3 million for the full year ended December 31, 2022, an increase of $11.1 million from $29.2 million for the same period in 2021. The increase in operating expenses was primarily due to advancing the development of onvansertib through chemistry, manufacturing, and controls (CMC) activities, pharmacology and other development programs, salaries and staff costs primarily due to increased headcount, stock-based compensation for additional grants to employees and higher facility costs for insurance and the amending of our operation lease.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">References</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.66pt">H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross, and F. Kabbinavar&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Bevacizumab Plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#59; The New England Journal of Medicine, Vol. 350, Jun 3, 2004, pp. 2335-2342.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.66pt">Fairooz F. Kabbinavar, Joseph Schulz, Michael McCleod, Taral Patel, John T. Hamm, J. Randolph Hecht, Robert Mass, Brent Perrou, Betty Nelson, and William F. Novotny&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer&#58; Results of a Randomized Phase II Trial&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Journal of Clinical Oncology, Vol. 23, Jun 1, 2005, pp. 3697-3705.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.66pt">Giessen et al., Acta Oncologica 2015, 54&#58; 187-193</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.66pt">Cremolini et al., Lancet Oncol 2020, 21&#58; 497&#8211;507</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.66pt">Antoniotti et al., Correspondence Lancet Oncol June 2020</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">6.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.66pt">Bennouna et al., Lancet Oncol 2013&#59; 14&#58; 29&#8211;37</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">7.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.66pt">Hansen et al., Cancers 2021, 13, 1031</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">8.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.66pt">Tabernaro et al. Eur J Cancer, 2014, 50, 320-332</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">9.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.66pt">Van Cutsem et al., J. Clin. Oncol. 2012, 30,3499&#8211;3506</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">10.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:4.09pt">Tabenaro et al, Lancet Oncol 2015, 16, 499&#8211;508 </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">11.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:4.09pt">Beretta et al., Med Oncol 2013, 30&#58;486</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">About Cardiff Oncology, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as KRAS&#47;NRAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in triple negative breast cancer (TNBC) and small cell lung cancer (SCLC). These programs and the Company's broader development strategy is designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">https&#58;&#47;&#47;www.cardiffoncology.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Forward-Looking Statements</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as &#34;anticipate,&#34; &#34;believe,&#34; &#34;forecast,&#34; &#34;estimated&#34; and &#34;intend&#34; or other similar terms or expressions that concern Cardiff Oncology's expectations, strategy, plans or intentions. These forward-looking statements are based on Cardiff Oncology's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results&#59; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidate&#59; risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm our financial condition and increase our costs and expenses&#59; uncertainties of government or third party payer reimbursement&#59; dependence on key personnel&#59; limited experience in marketing and sales&#59; substantial competition&#59; uncertainties of patent protection and litigation&#59; dependence upon third parties&#59; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that our product candidate will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that any precision medicine therapeutics will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Cardiff Oncology's Form 10-K for the year ended December 31, 2022, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Cardiff Oncology does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Cardiff Oncology Contact&#58; </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">James Levine</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Chief Financial Officer </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">858 952-7670 </font></div><div><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">jlevine&#64;cardiffoncology.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">   </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Investor Contact&#58; </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Kiki Patel, PharmD</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Gilmartin Group </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">508 320-1110</font></div><div><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Kiki&#64;gilmartinir.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Media Contact&#58; </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Richa Kumari</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Taft Communications</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">551 344-5592  </font></div><div><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">richa&#64;taftcommunications.co</font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">m</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ie0c292163e3b43e1959d3660aebead12_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Cardiff Oncology, Inc.</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Condensed Statements of Operations</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(in thousands, except for per share amounts)</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font><br></font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:72.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.734%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,107&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,376&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,181&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,838&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,288&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,214&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,902)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,855)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,581&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) from change in fair value of derivative financial instruments&#8212;warrants</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(383)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss </font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,704)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,291)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,728)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,315)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share &#8212; basic and diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.89)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.73)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8212; basic and diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,600&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,030&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div id="ie0c292163e3b43e1959d3660aebead12_7"></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Cardiff Oncology, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Condensed Balance Sheets</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(in thousands)</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font><br></font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:72.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.734%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,347&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,943&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,920&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,878&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable and unbilled receivable</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,246&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,771&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,284&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,127&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,269&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,251&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,796&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,387&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,191&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,544&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and Stockholders&#8217; Equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,956&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,439&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,177&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,527&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,808&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,559&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,568&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,848&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,127&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,343&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,417&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,191&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,544&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div id="ie0c292163e3b43e1959d3660aebead12_10"></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Cardiff Oncology, Inc.</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Condensed Statements of Cash Flows</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(in thousands)</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font><br></font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,704)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,291)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of fixed assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,256&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,234&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premiums on short-term investments</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,607&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative financial instruments&#8212;warrants</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(285)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Release of clinical trial funding commitment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,032&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(380)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,789)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,820)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,040)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net capital expenditures</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(892)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(205)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net purchases, maturities and sales of short-term investments</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,041&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131,243)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,149&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131,448)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of common stock, net of expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,187&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of options</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of warrants</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,450&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,404&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,038)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents&#8212;Beginning of period</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,943&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,981&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents&#8212;End of period</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,347&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,943&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>crdf-20230302.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:538b48b5-ef5a-4299-8be5-13fa1ff9c664,g:b76e2ec4-f994-43cd-8855-d451b90cc959-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:crdf="http://www.cardiffoncology.com/20230302" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cardiffoncology.com/20230302">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20230302_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20230302_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.cardiffoncology.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>crdf-20230302_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:538b48b5-ef5a-4299-8be5-13fa1ff9c664,g:b76e2ec4-f994-43cd-8855-d451b90cc959-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_335ec32b-cb73-4bbb-9eb9-3d519957be8c_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_47a8488f-1d60-4d28-a27c-42b0c1e05c3c_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_fb5bcc23-bc3b-40c2-9872-7df40802b3d5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_1c4bc973-2f11-4b53-af8c-26a72e304f2d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3776d6e6-a744-4dd2-8d4a-d92f90f2a450_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_b55ada4e-5992-4302-bc48-5c8dda36bf63_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_455d483f-e7a5-41a3-acfa-964ff0c48ec7_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_7cd0aae4-5043-468c-bc2d-2c062cb4390a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_879015d6-dbcf-4867-b952-cb3b7d6ff056_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_110f7a8b-24ab-44a7-b811-28f0df3dac75_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_9dae3331-20fc-4c24-8f2e-3760e208809b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_95ed9b29-3249-46b3-ba58-b78edc82735d_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_085f5e18-e77c-4e3d-ad1c-676214ba2440_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_402d3a44-6b66-4574-8a01-c603705b7f5c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_5ae6332f-2df1-40f4-891e-901d1172e686_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_4b427ab0-86b7-437a-9211-c4a96d607f1b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_7e705e55-c0e2-4e71-8ea3-3a8eda23c486_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_20752920-8156-4517-942c-06bf207de52a_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_211e8f58-141d-439a-882f-fdc7d6134f18_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_5a369c32-f35c-455c-9714-bc2d3e6f069e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_51dfefc6-1d3b-4e1a-a172-cd480ef338a6_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>crdf-20230302_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:538b48b5-ef5a-4299-8be5-13fa1ff9c664,g:b76e2ec4-f994-43cd-8855-d451b90cc959-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/Cover" xlink:type="simple" xlink:href="crdf-20230302.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_91d7ce90-c52d-4a72-80da-dbf93132c550" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1edccb57-4d83-4f35-8fdc-fec044640405" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_91d7ce90-c52d-4a72-80da-dbf93132c550" xlink:to="loc_dei_DocumentType_1edccb57-4d83-4f35-8fdc-fec044640405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_edc22cae-cbf1-49d4-bbe8-771b15141328" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_91d7ce90-c52d-4a72-80da-dbf93132c550" xlink:to="loc_dei_DocumentPeriodEndDate_edc22cae-cbf1-49d4-bbe8-771b15141328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_4efdd8b6-2aca-41c6-a801-d92754fa8ed7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_91d7ce90-c52d-4a72-80da-dbf93132c550" xlink:to="loc_dei_EntityRegistrantName_4efdd8b6-2aca-41c6-a801-d92754fa8ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_8f93efe3-d06d-479e-a314-879408be14bd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_91d7ce90-c52d-4a72-80da-dbf93132c550" xlink:to="loc_dei_EntityFileNumber_8f93efe3-d06d-479e-a314-879408be14bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_400955af-0e76-47f4-83bd-1a6b28bf5e0f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_91d7ce90-c52d-4a72-80da-dbf93132c550" xlink:to="loc_dei_EntityTaxIdentificationNumber_400955af-0e76-47f4-83bd-1a6b28bf5e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_74890b8e-8924-4381-a2af-cc6acb9edd29" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_91d7ce90-c52d-4a72-80da-dbf93132c550" xlink:to="loc_dei_EntityAddressAddressLine1_74890b8e-8924-4381-a2af-cc6acb9edd29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_cc42b9a5-8df4-4eec-9028-0bb75f80fe8a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_91d7ce90-c52d-4a72-80da-dbf93132c550" xlink:to="loc_dei_EntityAddressStateOrProvince_cc42b9a5-8df4-4eec-9028-0bb75f80fe8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ad9b8843-5a37-47e8-8806-ca7080478087" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_91d7ce90-c52d-4a72-80da-dbf93132c550" xlink:to="loc_dei_EntityAddressPostalZipCode_ad9b8843-5a37-47e8-8806-ca7080478087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_eaed13be-e116-474c-9dff-c8087acf4094" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_91d7ce90-c52d-4a72-80da-dbf93132c550" xlink:to="loc_dei_EntityAddressCityOrTown_eaed13be-e116-474c-9dff-c8087acf4094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_e3e96ea2-f4a5-41eb-971e-f2d53357399e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_91d7ce90-c52d-4a72-80da-dbf93132c550" xlink:to="loc_dei_CityAreaCode_e3e96ea2-f4a5-41eb-971e-f2d53357399e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_8168600b-0f6c-4c3e-a824-7eeabc9d4dd7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_91d7ce90-c52d-4a72-80da-dbf93132c550" xlink:to="loc_dei_LocalPhoneNumber_8168600b-0f6c-4c3e-a824-7eeabc9d4dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_539b439c-f2b1-4100-8027-f46a6a3eee25" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_91d7ce90-c52d-4a72-80da-dbf93132c550" xlink:to="loc_dei_Security12bTitle_539b439c-f2b1-4100-8027-f46a6a3eee25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_8cda362f-554a-4a46-b9c1-24836453a227" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_91d7ce90-c52d-4a72-80da-dbf93132c550" xlink:to="loc_dei_TradingSymbol_8cda362f-554a-4a46-b9c1-24836453a227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_49ce5e6d-4cb3-4682-b133-e03555c858a8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_91d7ce90-c52d-4a72-80da-dbf93132c550" xlink:to="loc_dei_WrittenCommunications_49ce5e6d-4cb3-4682-b133-e03555c858a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_85a482a3-004a-42a2-9a08-8f2559ce47c1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_91d7ce90-c52d-4a72-80da-dbf93132c550" xlink:to="loc_dei_SolicitingMaterial_85a482a3-004a-42a2-9a08-8f2559ce47c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_7b748d96-a986-4fe6-ac0d-f29b0a0d13eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_91d7ce90-c52d-4a72-80da-dbf93132c550" xlink:to="loc_dei_PreCommencementTenderOffer_7b748d96-a986-4fe6-ac0d-f29b0a0d13eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_05a5f941-5b35-42f7-b5c7-5070c13b1590" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_91d7ce90-c52d-4a72-80da-dbf93132c550" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_05a5f941-5b35-42f7-b5c7-5070c13b1590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_39d5b6f0-cd73-4cae-85e4-327066a4b781" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_91d7ce90-c52d-4a72-80da-dbf93132c550" xlink:to="loc_dei_EntityEmergingGrowthCompany_39d5b6f0-cd73-4cae-85e4-327066a4b781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d2127712-64de-4bc8-9ad4-09514d418091" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_91d7ce90-c52d-4a72-80da-dbf93132c550" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d2127712-64de-4bc8-9ad4-09514d418091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d4228873-23b5-4b1a-8d11-065a711c7afd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_91d7ce90-c52d-4a72-80da-dbf93132c550" xlink:to="loc_dei_EntityCentralIndexKey_d4228873-23b5-4b1a-8d11-065a711c7afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_8bc33760-7af6-42f7-a9f8-beecf6c4e6eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_91d7ce90-c52d-4a72-80da-dbf93132c550" xlink:to="loc_dei_AmendmentFlag_8bc33760-7af6-42f7-a9f8-beecf6c4e6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>crdf-20230302_g1.jpg
<TEXT>
begin 644 crdf-20230302_g1.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  N *8# 2(  A$! Q$!_\0
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M4BI0=TSCE%Q;C)6:"BBBK)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKA;[^TO!?BC5]833I-6T;4S#)/\ 8^;BU=(Q'GR_XU(4'Y>1SP:[JBLJE/G2
ML[-:HZ*-;V3=U=-6:\KI_FCR_P :?$JTUCPWJ-KI0"V4\#07.L:B&MK2V#J0
M>7 9WP>$4'G%0>#?&5C_ &M=1Z W]MF2V@5[5P;2Z3RX]JR>7*%W1L,'<.F:
MT?BFUOIOB+P?K6J6[3:#I]Q<-=R>09D@9HL12.H!P V?FQP2*SO%FOZ1XT\9
M>#;?P[<0ZOJ=CJ4=Y<W5B/,6WM/*D#AY5X4,67Y<\\<5G+ ^V2G*;YEJFK:;
MK9I]&[W[G+4S1TI.C3BE!-+E=W*5[:W36W2RZ,ZA-6LOAWX=U'6?%.H6>D03
M7+7,KR2_)&6P%C!/+-QT R2< &D\&?%SPG\0-0N+#0]6^TW]O'YTEI/;RVTP
MCW;=X25%8KGC< 1R/45QOBJW@U_]IGPGINKJLVG:?H-SJNG6\P!C>^\^.,O@
M\,Z1G([KN)%=7\6/%]QX+\.P7.EVT%QK^HWEOI&G?:%/EK-<2A%9R.=B\N1W
MV8XSD:4:4:,%3CT-JE1U).;ZG;T5\O\ Q \>>+/ >I>/[#3O&-]KESI/A^Q)
MDNH;9?)U*ZN_+38J1 *-FTA3N^^,YZUW5R/%EUXXLO!#^+KN&6XLY=?U74[:
M"%)(8]Z11VEIE"$CWAV+.'? ^]EN-C,[J;XI>&K?5I]-EU!H[N+5(=%*^1(0
M;R6(2I$"%(Y0@YZ#H3FIYOB/X<@U;5=.?4@L^DP&YU"7RI/L]H@4,1+/M\M&
MVD-L+!L<XQS7S_\ "7Q%J;:YHD.GZ[/>VWBCQGK5S<:B8XP][:6ML8D8[5"C
M+1Q'Y0!GL!Q7.-X/OM2^ NHW/_"6Z[.?%WBX68@E-L4F5]4^S[V_<9+-&FXX
M(&57 "Y4@'UIX=\26/BK2(M3TYIVLI<['N+66W+ '&X+(JMM/9L8(Y!(KD+?
M]H+X>W6J+81^)K=F:7R%NO*E%FTF<;!<E?)+9XP'SFN<_:#2]\*_ '4+/^U]
M0OU:6UL[W5+ED%R;:6ZC29F:-44?([+D*, _C6_\8K/P_P"'_@1XHL9K.WAT
M2+2);:"SC0!"Q0K#'&!_$7*!<<[B,<T >CT5\T:%J'C[5)O%>D77BNZT/3_"
MOAW3/M4UO%"UT;[[$99 &D1@%)8%\C<<(%*Y;.WX%\7>*_C%-HVE-KMSX;CL
MO#.FZKJMYIL4(N;J[NXV9%7S$=4C41LQPN26 X Y /?*Q[KQ9IMGXIT_P[+,
MPU:^MIKN&%48@Q1% [%L8',BCGKFO+;G4O$7BG7O&&GQ^-+KP_8>#;2&W>^@
MM[<O>7C6PG>XF#QE1$JLH\M N3O.0,5YW/\ %K5EO(_'TUE$VM6GP]L&6!N(
MEN]0O%5"1V7,:,1UVG% 'U=17@WB36/'/PZ\1#1M,U^Z\<:K?^&M2U$6=];P
M*8+N#RO*>,1(IV2-(RB-L\J,'K63H=YXV\4:AXDMO#_C;Q%<QV/AL2%M2TV"
MW/\ :\BOY:*KVROL 4,0O .!D\B@#Z/HKQGX>_$;4_C-JVD7.DWCV6@V6BQW
M&JR0J/WNH7,*E+?.,CR4)=MI'+QCUKU;2=/N=/$PGU":_5FRGG*H,8R3M! Y
M'('//')-(#0HHHH **** $(# @C(JMI^EV6DPM%8VD%G$S%REO$L:ECU. .M
M6J*!65[G,>-_AQH/Q"CL1K%K(US82&:SO;6XDMKFU<C!,<L;*ZY  (!P<#/0
M5C_\*+\(-H=]ILEG>7!O9X;N?4+C4;B2^::(YBD^TLYD#(?NX88R<=3GOZ*!
MG 1_ OP=%!>Q+ITI%[)9RW3O=2O)</;2M+$\CLQ9VWLS,6)+$\YK3\5?"WP[
MXTUFUU74[69KZWMWL_-M[N6#SK=R&:&41L/,C) .ULCKZG/644 <AH_PJ\.>
M';C2+C3;'[/+I'VTV(\URD1NY!).<9YRPXST' Q7/Z7\%AIW@?X?^'&U3S4\
M,ZA;ZA<3>3@WDD:R-P,_+F5U?OPN/>O3Z* *FJZ59ZYIEUIVH6T=Y8W430SV
M\RADD1AAE([@@UQ6B_ OPEHFH65TL&H7ZV#A[&UU34[F\MK-A]UH8I9&1".Q
M R.V*] HH YK_A7FB>7XJ3[/)CQ-G^TV\YMTN81#P<_+\B@<8QUK$U?X&^%-
M8NK"X,6H:?+:64>F%M,U*XM#<6J#"P3&)U\Q![\^]>@44 <)K7P1\(:]?27%
MQ83QI/%#!=6EK>30VUY'$,1+/$CA) HX 8'C@Y'%:.H?"_PUJTWB&2]TU;D:
M]:P65_&[MLDAA#^6J@'Y,;V.5P<X/85U5% 'E?B+X.R:;X?NSX1NKS^V[F:V
M^V7>I:O<M=7EK$^6M1=L7DA!!;!3H2>Y)J/P'\/==\+ZYXJ\2)8V6FW6H6$-
MM:Z,FISWD<DL/F%99YY%!!)<+A5P%&?F)X]8HH X[X3_  ]@^&/@BRT6/RGN
@MSW-[/"FQ9KF1B\K@=EW'"CLJJ.U=C110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
MB5!.1PT*&@H    -24A$4@  "#P   )$" (   !_LS'E    "7!(67,  40P
M  !9,@$<[ &S  !%KDE$051XG.S<08X<R](FUMZAH)D$S;277HF@#6A56H#F
M)1#W@H^/+&9%97BX?69^#G+4X*LP,_>(C/3OO_T_/@        +\C^H"
M    ?A!:        $806      ! !*$%       006@!      !$$%H
M   1A!8      $ $H04      !!!: $      $006@       !&$%@
M0 2A!0      $$%H 0      1!!:        $806      ! !*$%       0
M06@!      !$$%H        1A!8      $ $H04      !!!: $      $00
M6@       !&$%@      0 2A!0      $$%H 0      1!!:        $806
M      ! !*$%       006@!      !$$%H        1A!8      $ $H04
M     !!!: $      $006@       !&$%@      0 2A!0      $$%H 0
M    1!!:        $806      ! !*$%       006@!      !$$%H
M   1A!8      $ $H04      !!!: $      $006@       !&$%@
M0 2A!0      $$%H 0      1!!:        $806      ! !*$%       0
M06@!      !$$%H        1A!8      $ $H04      !!!: $      $00
M6@       !&$%@      0 2A!0      $$%H 0      1!!:        $806
M      ! !*$%       006@!      !$$%H        1A!8      $ $H04
M     !!!: $      $006@       !&$%@      0 2A!0      $$%H 0
M    1!!:        $806      ! !*$%       006@!      !$$%H
M   1A!8      $ $H04      !!!: $      $006@       !&$%@
M0 2A!0      $$%H 0      1!!:        $806      ! !*$%       0
M06@!      !$$%H        1A!8      $ $H04      !!!: $      $00
M6@       !&$%@      0 2A!0      $$%H 0      1!!:        $806
M      ! !*$%       006A!L?_W?_Z?5S[590(     \#BA!04N!A4R#
M  " HP@MV.=^5B&]       83&C!#D_$%:(+     (!AA!8\Z^FX0G0!
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MEL'G^X-; P     XA-#B%"5G^IN/]4_H$0    !@,*'%$8XZRC^J60    "
M2806PQU[@G]LXP      ?0DMQG)J_V$(      "M""T&*CFICSVL-PT
M@"Z$%M,XH/^4L0      Y!-:S.%<_DM&!     "03&@Q@;/XZTIFU7=<
M   ["2UZ<P3_'G,#      @DM&C,L?M-!@@     $$5HT9+3]H4,$P     @
MA-"B&2?L3RB9Z@F#!0    #X%J%%)P[6'V6\      "UA!8].$_?QIP!
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M     %PDM*CG4'L\2PP     <(70HI[C[!-890    " +PDMZCG+/H2%!@
M  !X36A1S/\!_CDL-     # :T*+8@ZRCV*Y 0    !>$%H4<X1]%*$%
M , +0HMBCK!/8\4!     /Y&:%',$?9IK#@     P-\(+8HYOSZ01?_I__M_
M_M?7G^H" 0   ("MA!:5_!_=G\FB?YE52"\     X$Q"BTI"BS,=N^AO9!6B
M"P     XBM"BDM#B3&>N^_W$0G0!     .,)+2J=>7C-:>N^,*X070    #
M;$*+2J<=7O./<];]H;A"= $     4PDM*IUS>,VO3ECW#7&%W (     YA%:
M5#KA\)H_C5_WG8F%Z (     )A%:5!I_>,VG!J][25PAN@    " ,806E08?
M7O/"R'4OCRM$%P     P@-"BTLC#:[XT;]W+4PJY!0    #,(+2H-._PFBLF
MK7MY."&Z     (!)A!:5)AU><]V,=2\/)$07     #"/T*+2C,-KOJO[NI>'
M$*(+     )A*:%&I^^$U[VF][N79@]P"      836E1J?7C-VYJN>WGD(+H
M    @/&$%I6:'EYS4[MU+X\91!<     < BA1:5VA]<LT6C=RZ,%T04
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M      XAM*@DM#C3U-#B?FU+C&\0      836E026IRI<-T/.= _I$T
MF$=H44EH<:9AH<62F3SAJ&8!    8 :A126AQ9FJUOW,$_PSNP8   " IH06
ME8069QH06JP:Q38G]PX     C0@M*@DMSM0]M%@UA\T.;Q\     6A!:5!):
MG*EO:+%J H4, 0    "2"2TJ"2W.5++N3NI_91H     D$EH44EH<2:A13G3
M     (!,0HM*0HLSM0LM%O:>PT      ()#0HI+0XDQ"BP0& @    "!A!:5
MA!9G$EHD,!      ""2TJ"2T.)/0(H&!     $ @H44EH<69A!8)# 0
M @DM*@DMSB2T2& @     !!(:%%):'$FH44" P$   " 0$*+2D*+,PDM$A@(
M      026E026IQ):)' 0      @D-"BDM#B3$*+! 8"     (&$%I6$%F<2
M6B0P$      ()+2H)+0XD] B@8$     0""A126AQ9F$%@D,!      ""2TJ
M"2W.)+1(8"      $$AH44EH<2:A10(# 0   (! 0HM*0HLS"2T2& @
M!!):5!):G$EHD<!      ""0T**2T.),0HL$!@(     @806E8069Q):)# 0
M      @DM*@DM#B3T"*!@0    ! (*%%):'%F806"0P$      ()+2H)+<XD
MM$A@(      02&A126AQ)J%% @,!    @$!"BTI"BS,)+1(8"      $$EI4
M$EJ<26B1P$      ()#0HI+0XDQ"BP0& @    "!A!:5A!9G$EHD,!
M""2TJ"2T.)/0(H&!     $ @H44EH<69A!8)# 0      @DM*@DMSB2T2& @
M     !!(:%%):'$FH44" P$   " 0$*+2D*+,PDM$A@(      026E026IRI
M9-&=T?_&0      @D-"BDM#B3$*+! 8"     (&$%L6$%J>I2JJ<T?_&0
M   @D-"BF/_8XC1"BQ & @    "!A!;%A!:G$5J$,!      ""2T*';G"%MN
MT4[A<CNC_XV!     $ @H44QH<51A!8Y# 0      @DMBMT\Q99;-%*[T,[H
M?V,@     !!(:%%/:'$(H46..],8.1      ""&TJ.<_MCA!^2H[IO^5:0
M  ! )J%%O?O'V7*+<"'K>_.D?L9AO2$     0#*A102YQ6 YBWO_O+[[J?WA
M[0,   ! /J%%A"7GVJ*+-&G+NBJTZ'AP?W+O     -"(T")%V@$W-P4NZ,*#
M^T;']V=V#0    !-"2U2+#SC%EW42E[*Y2?XR8?X1S4+     #,(+8(L/^P6
M76R6OX)/G.-G'N6?TRD     3"*T"/+$D;?<8H^'UNZ)Y7OH-#_G0']\@P
M   PF- B2Z.S;W[JM6K/G>F7G^P/;@T     #B&TR/+<\;?HX@E-%^OIP_W]
MY_OS.@(   " ,PDMXCR=6X@NEFB]3!N.^'>>\@]K!P    !.)K1(U/I ?+P-
MJ[-A@?8<]#]]UC^C"P    #@)Z%%J!DGX_-,6I=M)_Y/'/JW+AX     ^!NA
M1:X]Y^.BBXM&+L?.H_]5I_\=:P8     +A):Y-IV2BZZ>&WV*O3* 'I5"P
M  !\E] BFMRBW E+L#D)>"\,:%$D     '"3T"+=YD-ST<5/1XU]?R1P/15(
MK@T     6$MHT8/H8J<SIQV8#924)+$     @$)"BS;VGZ2''*;O9,@Y(4%.
M)0    # -D*+3ARI/\IX?RK\3QP*+PT     E!-:].-L?3DC_5-5>""Q
M ("3"2U:*CEDSS]G?X,QOE8>)X@K     . H0HO&'+C?(?BYKCQ:$%<
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MR@\#\BM<8EM<T2NZV%GA;-O.1_S,@"JU=^CXA\.,9^.,+OK:]K5KI8!,GF
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M%KRI/'7H$E=\3$DL1!<YRD\N')1 K)(;;<8M/^,1-Z"%1JKVS(R]"AS+4PB
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MMZ27,=-;ZX2Q5/7H0?&0;3VV&&.+(M^N<VVIY07 >X06\,/]T_:.!^YKG3G
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M9'DOY07<ES#&DN(W-)500]_R+IK118BT.RA3^)0"2WI;52^9*YM@V&02VE'
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M9Y$MQA)>9%I5R;-:4N'F^['<^/DLV0]]VX>_$5I 2[**=IYX$2E\+TFKO[R
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M,=YT0H]PG= "H%+YV]NPE\7R!M_NNG"8L:NY1/GJWQ]@[=*$;X_P\BZ:T<4
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MT04 D.F]-XT6+QM]^^I;.>PGM   H),9/_9F= $ 9)H:6O3MJVG94$5H 0!
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MH04  %3R,Q4 >-J>V*#P4SW@_QC0 I036@    # <.6YPOBXXA\SNH!:0@L
M    F*\\8)!8=&D$:@DM     . (Y3'#X,3BPW]F 8L(+0    #@%.5AP\BX
MXL-_9@'K""T     X"SEP<.\(_YA[4 AH04     '*<\?IATOC^O(R@DM
M  " 0Y5'$0,.]Z?V!56$%@    !PNO)DHN^9_NSN8#^A!0    #P0WE0T>Y
M?W9W4$)H 0    #\%T'%12?T")L)+0    " OQ)4 #L)+0    " JT04P*.$
M%@      0 2A!0      $$%H 0      1!!:        $806      ! !*$%
M       006@!      !$$%H        1A!8      $ $H04      !!!: $
M     $006@       !&$%@      0 2A!0      $$%H 0      1!!:
M    $806      ! !*$%       006@!      !$$%H        1A!8
M $ $H04      !!!: $      $006@       !&$%@      0 2A!0
M$$%H 0      1!!:        $806      ! !*$%       006@!      !$
M$%H        1A!8      $ $H04      !!!: $      $006@       !&$
M%@      0 2A!0      $$%H 0      1!!:        $806      ! !*$%
M       006@!      !$$%H        1A!8      $ $H04      !!!: $
M     $006@       !&$%@      0 2A!0      $$%H 0      1!!:
M    $806      ! !*$%       006@!      !$$%H        1A!8
M $ $H04      !!!: $      $006@       !&$%@      0 2A!0
M$$%H 0      1!!:    _W][=BP     ,,C?>AH[2B,  ( %:0$      "Q(
M"P      8$%:        "]("      !8D!8      ,""M        !:D!0
M    L" M      " !6D!       L2 L      &!!6@        O2 @
M6) 6      # @K0        6I 4      + @+0      @ 5I 0      +$@+
M      !@05H        +T@(      %B0%@      P(*T        %J0%
M  "P("T      ( %:0$      "Q("P      8$%:        "]("      !8
MD!8      ,""M        !:D!0      L" M      " !6D!       L2 L
M     &!!6@        O2 @      6) 6      # 0NM#.\ATCB[O     $E%
&3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140705578048496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar.  02,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cardiff Oncology,&#160;Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-2004382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11055 Flintkote Avenue<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">952-7570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CRDF<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001213037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>crdf-20230302_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="crdf-20230302.xsd" xlink:type="simple"/>
    <context id="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2023-03-02</startDate>
            <endDate>2023-03-02</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM180L2ZyYWc6ZWU2MDNkMGZjZGI5NDBhMmJkMjEyOTM4YWI1MGVhYTUvdGFibGU6YzViZTc3ZjA5MmVlNDBiNmE3MTc2OTk0YTk5NmJhN2EvdGFibGVyYW5nZTpjNWJlNzdmMDkyZWU0MGI2YTcxNzY5OTRhOTk2YmE3YV8yLTEtMS0xLTQ2NjI2_2aa4ce15-8763-4ab7-8d4a-d4ad9336be6a">0001213037</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM180L2ZyYWc6ZWU2MDNkMGZjZGI5NDBhMmJkMjEyOTM4YWI1MGVhYTUvdGFibGU6YzViZTc3ZjA5MmVlNDBiNmE3MTc2OTk0YTk5NmJhN2EvdGFibGVyYW5nZTpjNWJlNzdmMDkyZWU0MGI2YTcxNzY5OTRhOTk2YmE3YV8zLTEtMS0xLTQ2NjI2_83ee30b4-39b7-4cf4-beb4-45d451ac7699">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGV4dHJlZ2lvbjo1MDc3MDc1ZjA0OTU0MjY3ODQ2OGJjYjRmNmYwOWQwMl8yNzcz_a3d28a2f-caa6-4e21-89e9-bb0411753406">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGV4dHJlZ2lvbjo1MDc3MDc1ZjA0OTU0MjY3ODQ2OGJjYjRmNmYwOWQwMl8yMjg_d9f6e7b9-b875-4e97-902b-edeadeda61cf">2023-03-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGV4dHJlZ2lvbjo1MDc3MDc1ZjA0OTU0MjY3ODQ2OGJjYjRmNmYwOWQwMl8yNzY5_7e53eb6e-79b6-4444-b469-cd8e22d38e61">Cardiff Oncology,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGFibGU6ZTQxYTdlNjQ2N2JkNDdkZDkwZGRhMGVkMmI3ZThjNmQvdGFibGVyYW5nZTplNDFhN2U2NDY3YmQ0N2RkOTBkZGEwZWQyYjdlOGM2ZF8wLTAtMS0xLTQ2NjI2_45842e66-2f80-4052-a4b4-fababe514695">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGFibGU6ZTQxYTdlNjQ2N2JkNDdkZDkwZGRhMGVkMmI3ZThjNmQvdGFibGVyYW5nZTplNDFhN2U2NDY3YmQ0N2RkOTBkZGEwZWQyYjdlOGM2ZF8wLTEtMS0xLTQ2NjI2_44114d42-d9e0-4d4e-a67e-520e94c4e67f">001-35558</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGFibGU6ZTQxYTdlNjQ2N2JkNDdkZDkwZGRhMGVkMmI3ZThjNmQvdGFibGVyYW5nZTplNDFhN2U2NDY3YmQ0N2RkOTBkZGEwZWQyYjdlOGM2ZF8wLTItMS0xLTQ2NjI2_614711e3-d0c3-4d43-afd9-9b31d1c4497b">27-2004382</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGV4dHJlZ2lvbjo1MDc3MDc1ZjA0OTU0MjY3ODQ2OGJjYjRmNmYwOWQwMl8yNzgx_dfd9a8f7-8cbb-4e36-94d1-04c9c472cb22">11055 Flintkote Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGV4dHJlZ2lvbjo1MDc3MDc1ZjA0OTU0MjY3ODQ2OGJjYjRmNmYwOWQwMl8yNzgy_3f8117ae-2c3c-47ba-b51b-3b0d378f1722">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGV4dHJlZ2lvbjo1MDc3MDc1ZjA0OTU0MjY3ODQ2OGJjYjRmNmYwOWQwMl8yNzc2_9f7ac7c1-8acd-4bed-97c0-fc1ca095f134">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGV4dHJlZ2lvbjo1MDc3MDc1ZjA0OTU0MjY3ODQ2OGJjYjRmNmYwOWQwMl8yNzc3_152a0c53-1c49-4aef-9a36-e345d240c664">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGV4dHJlZ2lvbjo1MDc3MDc1ZjA0OTU0MjY3ODQ2OGJjYjRmNmYwOWQwMl8yNzgz_d6ba076c-163c-416c-b852-39a1cd7d107c">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGV4dHJlZ2lvbjo1MDc3MDc1ZjA0OTU0MjY3ODQ2OGJjYjRmNmYwOWQwMl8yNzc5_e1409b7e-1097-4a03-92e5-b30074e684e3">952-7570</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGFibGU6NzJmNWNhYWFjMTJmNDMwZDgyNzdmMDdiODJhMDdhYzAvdGFibGVyYW5nZTo3MmY1Y2FhYWMxMmY0MzBkODI3N2YwN2I4MmEwN2FjMF8xLTAtMS0xLTQ2NjI2_865f921f-15bf-4164-90ef-1fc83916dc9c">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGFibGU6NzJmNWNhYWFjMTJmNDMwZDgyNzdmMDdiODJhMDdhYzAvdGFibGVyYW5nZTo3MmY1Y2FhYWMxMmY0MzBkODI3N2YwN2I4MmEwN2FjMF8xLTItMS0xLTQ2NjI2_03b629bc-e456-425e-a2a8-3b911a70b7e9">CRDF</dei:TradingSymbol>
    <dei:WrittenCommunications
      contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGV4dHJlZ2lvbjo1MDc3MDc1ZjA0OTU0MjY3ODQ2OGJjYjRmNmYwOWQwMl8yNzcw_8ac3a7e8-b7cf-470c-b2c1-230ad3c1bd39">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGV4dHJlZ2lvbjo1MDc3MDc1ZjA0OTU0MjY3ODQ2OGJjYjRmNmYwOWQwMl8yNzcx_e48b704f-cb96-4fb9-bca9-71f609438329">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGV4dHJlZ2lvbjo1MDc3MDc1ZjA0OTU0MjY3ODQ2OGJjYjRmNmYwOWQwMl8yNzcy_bbe295b6-7acd-47de-9fe0-f2ffa85b47b8">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGV4dHJlZ2lvbjo1MDc3MDc1ZjA0OTU0MjY3ODQ2OGJjYjRmNmYwOWQwMl8yNzgw_5a6a22e0-7475-48e4-bb61-03c22f548180">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2N2VmZGUyMjVjNjQ0ODY4NTI0MDBlNWU2YWQwNGMzL3NlYzo1NjdlZmRlMjI1YzY0NDg2ODUyNDAwZTVlNmFkMDRjM18xL2ZyYWc6NTA3NzA3NWYwNDk1NDI2Nzg0NjhiY2I0ZjZmMDlkMDIvdGV4dHJlZ2lvbjo1MDc3MDc1ZjA0OTU0MjY3ODQ2OGJjYjRmNmYwOWQwMl8yNzc0_e03f7c07-6b6a-4ffe-bd1a-f4ec7bf3e576">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M#8#[B89MU+[CSH/U<7[R'U!+ P04    " "]@6)6GZ ;\+$"  #B#   #0
M 'AL+W-T>6QE<RYX;6S=5VUKVS 0_BM"/V!N8FKBD1BV0&&PC4+S85^56'8$
M>O%DN7/ZZZ>S;"=I=67=A['-H<G=/;J[1W<GF:Y;=Y+\X<BY([V2NMW0HW/-
M^R1I#T>N6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZF
MTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,7
M8&F? KP(&K <XRBAC05C$C*$[_VX_!DP::U7A90SP24-AF+=,.>XU7=>&18/
MQA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<
M45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,
M%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>
M]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M
M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7>>9 ]IV03NA1.XJR
MY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD<VW
ML,\E=,E[7FY'U=;[021>\%G'!QR>(W?#$T<PGX#%$<"P/!@#S"=X87G^I_VL
MT/T$#..VBB(KU&>%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/
MAG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+
MV.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0
MIA@"IQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04    " "]@6)6EXJ[
M',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6
M!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV
M)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O
M@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=
MI7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    (
M +V!8E:JQ"(6,P$  "("   /    >&PO=V]R:V)O;VLN>&ULC5'1;L(P#/R5
M*A^P%K0A#5%>0-N0I@V-B??0NM0BB2O'A8VOG]NJ&M)>]I3<V;K<7187XM.!
MZ)1\>1=B;FJ19IZFL:C!VWA'#02=5,3>BD(^IK%AL&6L <2[=)IEL]1;#&:Y
M&+6VG-X"$B@$*2C9$7N$2_R==S Y8\0#.I3OW/1W!R;Q&-#C%<K<9":)-5U>
MB/%*0:S;%4S.Y68R#/; @L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\
M@RX/J!5Z0B? :ROPS-0V&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'!
M=09#K+&))@G60VY6= ;N\N@#FW+()FKJIBF>HPYX4P[V1D\E5!B@?%.9J+SV
M4VPYZ8Y>9WK_,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04    " "]@6)6)!Z;
MHJT   #X 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P
M#(6O$N4 -5"I0P5,75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=N
MH+;S)$9K!LIDR^SO *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFB
MG#S^0W1UW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6
M<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ O8%B
M5F60>9(9 0  SP,  !,   !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O
M$F5;)2XL6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1
ML.B=]=B4'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3K
MU3.T<F^I>.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY8
M4(JKA%SY'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"
MJ;$#(&?KT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R
M]>S[04Y;@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>
M?P%02P$"% ,4    " "]@6)6!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( +V!8E9&EG>A[@   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( +V!8E:97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ O8%B5NKJ!^4;!   V@\  !@
M         ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( +V!8E:?H!OPL0(  .(,   -              "  5X,  !X;"]S='EL
M97,N>&UL4$L! A0#%     @ O8%B5I>*NQS     $P(   L
M ( !.@\  %]R96QS+RYR96QS4$L! A0#%     @ O8%B5JK$(A8S 0  (@(
M  \              ( !(Q   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M +V!8E8D'INBK0   /@!   :              "  8,1  !X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( +V!8E9ED'F2&0$  ,\#   3
M              "  6@2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )
-  D /@(  +(3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>21</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="crdf-20230302.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="crdf-20230302.htm">crdf-20230302.htm</File>
    <File>crdf-20230302.xsd</File>
    <File>crdf-20230302_lab.xml</File>
    <File>crdf-20230302_pre.xml</File>
    <File>crdf3222-q42022pr.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>crdf-20230302_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="21">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "crdf-20230302.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 21
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "crdf-20230302.htm"
     ]
    },
    "labelLink": {
     "local": [
      "crdf-20230302_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "crdf-20230302_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "crdf-20230302.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 22,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 21,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "crdf",
   "nsuri": "http://www.cardiffoncology.com/20230302",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230302.htm",
      "contextRef": "ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.cardiffoncology.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230302.htm",
      "contextRef": "ibbdfb01af7d74d039bf7b23e1e405180_D20230302-20230302",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628280-23-006049-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-006049-xbrl.zip
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M-X0O%;] B$B=O<KX;1O38F>,@@0HGI YIMY/PT,<)1*6"):S0DH^#3H?<SS
MWTYST,&<LH,/?9Y0)(K%_)^A=_4Q5PZ#!,06MR8#:+Z3/7W,)7R<%%(.%@[^
M^../#XF7^/S B9B+A<!*BD0^%+(O/Q2RHNV030X^,.\*Q<G$YQ]SS(L'/IV4
M@C#@0( W+HD7>91]]!CC0?H1TBT8.Y'G9/6/DR9W/^8\VV:N+<G4U9FN,DDQ
M;5>WB<)EKDJ:;$@7E1DI-S3E4$#[HFKNE:H!T#<I0W,BZM<"QL=_\4D.>0R*
M9LKWB5T)KTY(\ZJMU(>L5[TZ/S9[C=XW8I'O_?/C;Y-Z[WO/ZGV5&I6V:K5J
M4KWRR;?.OI'VV=>1=5R_/E$LOWT=RE:/^>?]IE_OU>3V=5NR*AW2J'R;6)7#
MT7GKNV_UCR[KE6:O#B2?D/-)^\PIGD,Y]8IU63\^[YT?US2K\JE;[W^^K/>J
MDT:KKK;/:G+]^'NWW?IVQ8Z///OX6[%]_=T[;SG*>>]0J_>AW,HGS^I7E7K+
M(8W6I=1N76I6_W/7(M5IGN]0EQ:<MP8]Z^RS;UVS?KUR.8&ZI?IQC;1;SMBZ
M;FN-5K,+^4D;RFI_-R8GK6I2/Y7&)ZVOQ.K5R 6A5'4XC%9#+RI8I;:.#:92
M0!G*3$4IVH CN0,)ABF1H1?T#X6%3GW./CX$R&4"=H]\VLFA;"Q L>.DY'IC
MSK!+?3&LWSK]X4Z_7NIT0^%<D6P50Y?H6'5<%=L<'E5-*!?JZ$73S!T<'9Z<
M5I?ZN[ XOB/N\H@#9,?WP)( QU*<0CM(!$K!LI0 &'W,Q5Y_X M,3K_K1D)@
M%A H/XX9%%%8+".K_[;2*0UQ.(S2IU2]E:92F$G&STCAK"">PLSLR6/BV?5X
MA%*"^+U:L5S[:W' W,U\,/MJL?0!\#=DLR?0@U%2 6/C0!"%)?A'9OENTV[(
M9"M>G:7,GF>5%!88->/J#1L+<WA> -3/H#]EYX_LC0LY-Y]GJB[Z7H"[7-A$
M)=D8).]''DNZ)5F2_C^7OG?P(1Y0D"@[*D#N['-6R%)1PAS!0'1$G:04#_M]
M&DW>BU9@ZGN=H.0 6WD$Q2;4]ODLEQU&T!KLA+Y/!S$OS3Z\GRFR3/7B---[
M*+,#%-MADH3]D@8$@VV8> [UIY6D]67)MVW)2UE[$N!:PF8U3Y/S:5(A8<MI
MII$WI=7)4EZ^22ND94>S%Z8L!0)S:3YHE>#=QYR2N]/P:5/D08+BT/<8^E-*
M?]Y/TY-P4")+B0/*F!=T2A*2TRIN:2BDC)KKGM4].-=W]W63>'66#O2'46E6
MNPO2"2#?]_Q)Z=\MKP\88_$1:H9]&OQ[/P;["&0A\MSLQ=B[YIEPI8^CC#4Z
ME)-V[$SZB&#T-ZO6JE;0:>NP53W=>FI/J^5OS5JK5CU%AU8%5?\N__?0.JZB
M<J->KYV>UAK6!IL@K=6$,QIW09"2,-A'E3+X19IJ;A'1ZKU$_^M/N2B]WWKQ
M.&HTZU-2G\\8F[G F2NQ29-K/#.YK-:A8EW#_[/VR*I<RE:E1JSKCF3UNEZ;
MU"0PQ, \\B%?#<RG[RK[[V?_G/A7=B^4ZQ5'@?\RF%Y2HP7F4Z^M-"I?2>/X
M<Z_=:_:M?GO4 !KKOC&QKIWK"ZHP8E#B8H?2(E8YD;%A<A/;MJ3*LJXIJE3,
M'1CXKV6#Z4W*'R:3K"7E ('-JM5"S>J71K.U]>1^&4;QD 8)2D)TRAWAPV>,
MEA441DC6]MB[[(O014F7BY>&D9=X0$)U['3!CN;HT$D0),NFHCZZP1O7Q.M)
MG[!.11N;?!!&"=J;/7,*]BF/$\2OQ,1;E"9S]JZ$9DW:A!I[ 8#]DEKHU<QN
M7_1Z&7R#^U!G5V3#C$[P!/B$>?#*$+G>ZUPPTRURW08$-G0- -G4L2D1&W,F
M_!9&B[+CY@[J-'*ZB.RG,[&_#,T_,::\?@?%D7/'N;WHR/G>H)-#U$]6)2V:
M^*HZ&/^46Z+I@W&N\$I5RWH&U+//4S9YQXO%A&YB0<HK&ZQB1NI"YYK"[2+'
MNFF#^00_V%:+)G:8P0EABL&+,NAX&C'/=5$C$%W?F>QG E0+G/S.F55[U3$%
M]2U$0>BSZ$8$$(U1/.".F MBR N0E\0(%#ZHM^C=YIIU=Z@\:D3OT&2+8N8U
MHJTUV?*88F4]7]36F\-Y)FJG4T.KYH%F4SED,!:3.<LS9DM<#P<O/UD@O0@>
M Z"$$1B4Z=+::0)F53D<!DDT*8=LT>82DXUBOC7A@RB\$N7LJ+&5K3B<M[Z.
MVRWF TU X^=+J\(NSRN7H_/C9K=^_/VRWJ\IYZUNS^I_O;OBX%N5HZY%H&V5
MMM+N?Y4LTKQLM#Y=GA]71^=G7R=M:$/CN$[.CXS12>MP<<5!U0R5\&(1$]>0
M,'05P52U59 ?F]I<DT$7:. ,<)^.:,17@OUT##Q.O'WN+D%*AB:YEX58;2WI
M7X38WW+\'7D^A])M8/';6/KQ6+JS>J>JLJPRE6!F<AA+3.68%G6.-2)Q4W54
M7M1=L0(E8T73-.-AR^GGAM2KTQ@M.JY-%_"<5&N\B>_:XEM;%-^BK.JRS!7,
M)$<1XJM@ZC(3F[8B,]E155.W<P=$A]Z05,4@#RJ#731ZEBSK5(3W4CM$S V&
M29='J#>,O)AYZ<SA;ZK_[F?$2^J_%5U1#OM]+Q:Q@$BH*I0-]G>[C9SWM[76
M/$75_L /)SSZ34<6>-_>O,&?CK&H0P/O.GU^]XCAM; 0OO.<651IR KS[Y9E
M8,5*_ZN;2]SX"D%FB1PR%O$XGOXY 0+DG;1"?F5"L3.^8& R4,/5L>'8-E:Y
M4L2FRF0LJ8[IJ#IQ;$)R![(L:1HZ@FY*+D/0KH=7/!BN=B]?NU"5X6,C:H6C
MW9SC^"61FEPHKB'+.N68.(J#5=VFV-9D&RNVQ!3=<&5=B-0I='_%XYWPKA3M
MHY?JIM12;$1?HO#*2X/E7UE?.>3"='7JZ(Z,#>HPK-J<85-W).PZLD,E4W-E
M1<T=E _O=M*+]=&7,$ZH?^X-LBG%U]9#RH6L$2HYFH+!I3.Q2KF+30HHS155
M8T25Q"Z7W(%)9")O,1ZO6-N9=K)8V!E$, :] ?41'W-GF'A78KT';"H>+Z_F
M/#&YQ=VTG.XG\W:1]%]_&D36W\<HX3X?=,. HR#UP/:%(>\/A7F-:,0I#%_&
M?]N($*&-#Z&5KQ)!.M<7K&A322\Z6"X*?2S#)]O0"%9,*CM,9[*D.S 6#<UX
M]Y(P?Q*"Z_9%2.4.SP'^$KAK%UQ6)=/6.98E4P=PEQ1L$JYA6Y$D7>5% PQR
M '?H+%W3I1_B^S8M96\;+.X(F7M'802].XUWB-(U5'BDF:($X'91%M3(4"R,
M5N33>!;6]_BHAQ6!6)MI^ESD9A;EP2-HY6!E "C9LQ=#/P^=I/0\.DQ9JP%H
MFP;D,C$W>XBR.!&Q4V6ZX65G8D[4/ #F3P6'/!PX8AA/'W)"U#S1]!TA-N6L
M\A3Q,5/Y$8LE)>5V(Y2;_LSODEI.?.3:2]]CS.<OO/;RPTC(5+);8M/W#)NR
MOYPZW>R3 Y =/Q-0W0VJ?_FE(7DM"M!3K %MC5"LN;K^G&S__3K^M4!%1$5+
MLIXYG?3MT-^[G?%X$Y(W='CK^-7HD!X/]'KM#+$-8I69P:>[WZ;I4Z]IU/5F
M+]PZ66_&R)+4K6?E/KS;?YOE:\W(AF><_YNZ^Q.9V*FYO)/S?UD,H'7]N6^=
M6=WVV5&OWH+/E?KHO-*99 ?+,*]1^=R%O]WV]>&=&,!0J??;<IL<0=[Z&#Y+
M]>M/EXU*3;$(U$]J:KU?A;]0[A'0>#<<W"AJKDED%\N:[8JI716;$H='US$4
M4RXRQW1R!R(,*PS0:1(ZEZOF$-]&_F]H:+P\VW^_CM]]I%^O3YX1Z:<N3N;<
MO,'\&C!_)]1;4NPB,6T'<U4K8I5H'%-"#:S8IBQ37;)U;@+,-RM'=^%]ET;:
M3@RF-XC='HB]/PSX1BXVT?$6C1G]!Y7IP$NHC^HTNN3)&K' O\DI)"NW-6^"
MF'*7.Y?IPB =#*)P$'EB8X@=CI'-_7 DEE)%HEAPS>@V\%_(]7P1%>/%R!.G
MO#+.Q,)C[/6'?D(#'@YC?X)BFGBQ.TFS3S.$-G!_&A:?E3NW4WT(Y42(!I-9
MFAOZ0('()[;#>F*'Q.V*P/V]ZP4BR+RD%-,ENRWJW#OPG:W\I"=&S-.-Q3?K
M$WX&)8G2XI_&H.>.*CH#WQ4$1/A6PV :^1]OZ>FJFPAN&5T8U%&HS@ULZPXX
MI[KD8)LX,@9>4J8XLLT4L%J6XG\WM&-I<07_9?=KS0VO7_F]4<Y-QP.,L;D!
ML1"]T1S.UD3!@IUBXIT3N\1!77NRCLI'301BDH<75P>U+ #.<^#BD\0_O3)8
M/ 7CS8'.##IUT+:@<OTW3+S!Q/$%5PU;EU07.[8)GIPKSMURJ(EUV2U*IJH8
M"GG#Q-\&$V\' ^I/1\,*1)15BF4R!XH+9Q?>0*(JY;,WWU!QIU#Q2\2%H2B.
M6D\/?Q6.1=1P71'U_(:.4W2<7-@V)Z9F%[&>[D;2&<>FRR7L$M>EAF:KNFV\
MH>/O@HXP*+ S-RH63<=X)5(R?!OYNQ9@9AG>('.7(;,6QT,>O0'G?5M\1A<:
M+5)" "EU51SB:G 5VW91QI+B$.)JJ@'\?@/.5PZ<"L?JGO,(X)QF>/;MET\"
MCW.[&LC3(_ACY.I'),ZN$)$V,9.K&#=TU@(F1(8C>X*<=*X<"+Q$HRY/#TZZ
M,X?MQ0@(!7D3;>B@3A2.DJZ0O(&8UZ8Q8MR%BM*36!>?YN9]) TM']-^>SJ[
M@O;$B_K[=.YG]K*7'NLZ$,>ZBAU1<Q)-;$SN*?"^<]]O2A:"?9MOKNS\=-],
M]?XF_M2X_W4UF_;7LV^VG[7Y.&UR.6OQFX:]<4VD"RXIKNY(.B[:18I5L$"P
MS62*794[NNTJ7-.+#VC8K3CTI^8^,(3%GO![\<!;6L[JPOCF/G?$#9Y!F*J9
M8<S3MT LIXMFXMI%+YL#3D_B%\*4UN5/1.7IS9\".0)H(:1$_,J+(1^@!@T<
M,5%"'4<<)BM>%I=9,AJQ.%LN8P]N"U3VZ.*VP'DXR/^"$G\BFSE\U"KNSNS-
M>\'+MY:#!.8B")9OYGK$Y5MW2$J]K$&8R7$IXCX5QU(L7;IV2V5*GG2;A=I
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M#D(<!>Y6%8[W(;=30XPK33B%8WSW7WCD_8L8]GT^+H:1=WP,UI@"ZE;BP2N
MF<Z%K[M7;\'- 9O#U"?A7&C+-Y)!UK:,EV(GZ$4F\&R,_@K*<75>[,,K(V)?
M&9%4BOJ=>?):*5J0FH%ZODO6P%I"OTMFH_ XM;]KDKM])"/DA8-I"XS:ZRE0
MK_:9C%S]V/9<U3>@AEUM_N?$6PG')MY35']SV$8?F;_A7_=ZQ(J%<R[Z?X&#
MC.SFZMN[-XSUO>.,1D>S!92,,SMXOGT"A/=_#XPLZ]0[Q!Y8Z104/_G2G@]S
M',@#Y"]$2FK:U<?S]F&]21N$8PV''?.F2[;[?K:(5K#;[N7L"5!+ P04
M" "]@6)6I]:K[P,*  "L"@  %    &-R9&8M,C R,S S,#)?9S$N:G!GG9%Y
M/-3=&L!_8V;LVS#&GLH2V9*U+"/KI&3)3IM]R;Z,O421G<0;$B-+MC#&4H/"
M2(3"3!G9]\'8WC1(+N_G+O_<^_G<>[_G>?YZGG/.\SWG\-OA%,!I9'#9  "!
M0(#ST0(.QP!= $Q'=QQ'0(X"R@B%0B!09@8&>D969E96%F86%C9V+DXV=A@[
M"PLG@A/&#>?AX6'EX.5#P/FXX#SPXT- X*,]$"@3%,H$9V-A@__/'+X#8(R
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M3F3WUI8S/4/UN+HRX]3N:HR^5]^K[G'P!EAC0$V=L&;#WD=I-T]V^DAJI44
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M>%NK^IO%"_'.\,#1WL,/W4OW1/31WO\!4$L#!!0    ( +V!8E9W8JR^6"8
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M#.9$/N])5X;WQ#EZ(3 ,#$ZE[PO!@LB_!0/@LG#(@:Q1#X8,8^&N>\_$-UO
M1,(A6!T6".'A1(<R")6/JD&C]I6KB1!L"8.O0U]X@W H/)@Z<D#XP5".62B
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MF %O!\@$8[RE5[/(2SP.T&4(+%T$J)X 44 @S=!;;LN_HA'O53S^P]NZU8&
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MP'.0FLV*:?UCHM"3Q7LWQB+("@23< LNT"?U3.FH]D:G:JD1F6:U!4[="X<
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M*-+D AOMU2K/7S=!>=+#%AOSVX7F=V5A9B64-HCFN8^I7EN(%[]^U!O%&8>
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MT3QCO$JJN$"9X';;Z-2?F0DN:"*_0-PQL<=@:X/'#>P"'CNQ;9A!&# ?8DK
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MZE&JQQH13,[58PT.=N:$W<?.OBS4 ;H'/>7<PW^&X<C]Z?\!4$L! A0#%
M  @ O8%B5M?4FWH&%   WI@  !$              ( !     &-R9&8M,C R
M,S S,#(N:'1M4$L! A0#%     @ O8%B5MTW":]N @  @P<  !$
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M,0  8W)D9C,R,C(M<30R,#(R<'(N:'1M4$L%!@     &  8 B0$  &)8
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
